ScreenerHero
BAVABavarian Nordic A/S
CPH · DK · Healthcare · Biotechnology · bavarian-nordic.com
204.80DKK+6.67%Mkt Cap: 2.12B $P/E: 12.72

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human u…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap2.12B $
Enterprise Value1.83B $
Revenue (TTM)867.39M $
Gross Profit444.04M $
Net Income (TTM)200.33M $
Revenue/Share10.98 USD
Last Price204.80 DKK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.9K
CountryDK
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)12.72
P/E (Forward)18.83
PEG1.87
EV/EBITDA8.96
EV/Revenue2.10
P/S2.44
P/B1.17
EPS (TTM)15.10
EPS (Forward)10.20
52W Range
171.3046% of range244.80
52W High244.80 DKK
52W Low171.30 DKK
Profitability
Gross Margin48.83%
Oper. Margin-0.66%
EBITDA Margin23.50%
Profit Margin22.03%
ROE10.69%
ROA9.20%
Growth
Revenue Growth-21.40%
Earnings Growth-92.60%
Cash Flow & Leverage
Operating CF396.45M $
CapEx (TTM)197.98M $
FCF Margin-8.50%
FCF Yield-3.48%
Net Debt-313.59M $
Net Debt/EBITDA-1.54
Balance Sheet
Debt/Equity0.01
Current Ratio6.47
Quick Ratio3.50
Book Value/Sh164.47 DKK
Cash/Share29.97 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)267.50 DKK
Upside (mean)+30.6%
Target Range250.00 DKK – 280.00 DKK
DKK250.00+30.6% to meanDKK280.00
# Analysts4
Ownership
Shares Out.75.68M
Float76.35M
Insiders0.01%
Institutions34.21%
Technical
SMA 50181.59 (+12.8%)
SMA 200188.56 (+8.6%)
Beta0.94
S&P 52W Chg18.16%
Avg Vol (30d)154.77K
Avg Vol (10d)136.36K
Technical Indicators
RSI (14)66.7
MACD2.1266
MACD Signal0.2158
MACD Hist.+1.9108
BB Upper192.11 DKK
BB Middle180.49 DKK
BB Lower168.88 DKK
BB Width12.87%
ATR (14)4.007 DKK
Vol Ratio (20d)2.14x